<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1428">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142566</url>
  </required_header>
  <id_info>
    <org_study_id>ST-3370</org_study_id>
    <nct_id>NCT05142566</nct_id>
  </id_info>
  <brief_title>MANTA Ultrasound Closure Study</brief_title>
  <acronym>MANTA ULTRA</acronym>
  <official_title>Prospective Multicenter MANTA™ Vascular Closure Device Ultrasound Guided Closure Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essential Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teleflex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Essential Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the safety of MANTA Vascular Closure Device (VCD) ultrasound (U/S) guided closure&#xD;
      in patients undergoing elective TAVR procedures with planned percutaneous femoral arterial&#xD;
      access.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MANTA Vascular Closure Device is indicated for closure of femoral arterial access sites&#xD;
      while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD)&#xD;
      in endovascular catheterization procedures.&#xD;
&#xD;
      This study is being conducted to demonstrate the safety of U/S guided closure with MANTA VCD&#xD;
      following TAVR procedures utilizing large bore sheaths.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None (Open Label)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of any large bore access-site related VARC-2 major vascular complication</measure>
    <time_frame>within 30 days</time_frame>
    <description>adapted from VARC-2 Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Hemostasis</measure>
    <time_frame>During the procedure</time_frame>
    <description>The elapsed time between VCD deployment and first observed and confirmed arterial hemostasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Technical Success</measure>
    <time_frame>within 30 days</time_frame>
    <description>Percutaneous vascular closure is obtained without the use of unplanned endovascular or surgical intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Ambulation Success</measure>
    <time_frame>During procedure admission</time_frame>
    <description>If a previously ambulatory patient (until day of TAVI) is able to ambulate for at least 20 feet/6 meters without re-bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulation</measure>
    <time_frame>During procedure admission</time_frame>
    <description>The elapsed time between VCD deployment and when ambulation is achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Success</measure>
    <time_frame>within 30 days</time_frame>
    <description>Time to Hemostasis ≤10 minutes and no VACR-2 Major complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>During the procedure</time_frame>
    <description>Elapsed time from initial skin break to time when the post-deployment angiogram is completed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of any large bore access-site related VARC-2 minor vascular complication</measure>
    <time_frame>within 30 days</time_frame>
    <description>adapted from VARC-2 Criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Femoral Arteriotomy Closure</condition>
  <arm_group>
    <arm_group_label>Ultrasound Closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, single arm study using ultrasound guidance during MANTA device deployment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MANTA Vascular Closure Device</intervention_name>
    <description>Evaluate the safety of ultrasound guided deployment of MANTA VCD.</description>
    <arm_group_label>Ultrasound Closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Candidate for elective or planned (i.e., not emergent or urgent) percutaneous&#xD;
             transcatheter valve replacement (TAVR) via a 10-20F device or sheath (12-25F OD) with&#xD;
             common femoral artery approach&#xD;
&#xD;
          -  Vessel size would allow for access for the MANTA VCD based on vessel size as&#xD;
             determined by baseline CTA: minimum vessel diameter of 5mm for the 14F MANTA VCD and&#xD;
             6mm for the 18F MANTA VCD&#xD;
&#xD;
          -  Understand and sign the study specific written informed consent form and PHI&#xD;
             authorization&#xD;
&#xD;
          -  Able and willing to fulfill the follow-up requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients known to be pregnant or lactating&#xD;
&#xD;
          -  Patients who have a systemic infection or a local infection at or near the access site&#xD;
&#xD;
          -  Patients with significant anemia (hemoglobin ≤10 g/DL)&#xD;
&#xD;
          -  Patients who are morbidly obese or cachectic (BMI &gt;40 or &lt;20kg/m2)&#xD;
&#xD;
          -  Patients with a known bleeding disorder including thrombocytopenia (platelet count&#xD;
             &lt;100,000 cells/UL), thrombasthenia, hemophilia, or von Willebrand disease&#xD;
&#xD;
          -  Patients with allergy to bovine materials or any other device material, including&#xD;
             collagen and/or collagen products, polyglycolic or polylactic acid, stainless steel or&#xD;
             nickel&#xD;
&#xD;
          -  Patients with a femoral artery puncture in target groin within the prior 30 days,&#xD;
             prior vascular closure device placement in the target common femoral artery within 3&#xD;
             months, or any prior target femoral artery access-related complication&#xD;
&#xD;
          -  Patients who have undergone use of an intra-aortic balloon pump (IABP) through the&#xD;
             arterial access site within 30 days prior to the baseline evaluation.&#xD;
&#xD;
          -  Patients who have a Common Femoral Artery (CFA) with visible calcium and/or&#xD;
             tortuosity, as determined by baseline CTA, precluding safe access and likely to&#xD;
             interact with large bore access site arteriotomy, determined by investigator.&#xD;
&#xD;
          -  Patients with previous iliofemoral intervention in region of access site, including&#xD;
             but not limited to prior atherectomy, stenting, surgical or grafting procedures in the&#xD;
             access area&#xD;
&#xD;
          -  Patients in whom oral anticoagulation therapy cannot be stopped for the peri&#xD;
             procedural period or patients with INR &gt;1.8 at the time of the procedure&#xD;
&#xD;
          -  Patients who are unable to ambulate at least 6 meters without assistance at baseline&#xD;
&#xD;
          -  Patients with renal insufficiency (serum creatinine &gt;2.5 mg/dl) or on dialysis therapy&#xD;
&#xD;
          -  Patients with existing nerve damage in the ipsilateral leg&#xD;
&#xD;
          -  Patients with a further planned endovascular procedure within the next 30 days&#xD;
&#xD;
          -  Patients who have already participated in this IDE study&#xD;
&#xD;
          -  Patients who are currently participating in another clinical study of an unapproved&#xD;
             investigational device or drug that has not concluded the follow-up period or patient&#xD;
             currently participating in another clinical study likely to influence hemostasis and&#xD;
             vascular complications&#xD;
&#xD;
          -  Patients who cannot adhere to or complete the investigational protocol for any reason&#xD;
             including but not limited to geographical residence, psychiatric condition or life&#xD;
             threatening disease&#xD;
&#xD;
          -  Patients who have a common femoral artery &lt;5mm in diameter for the 14F MANTA VCD or &lt;6&#xD;
             mm in diameter for the 18F MANTA VCD, common femoral artery stenosis resulting in a&#xD;
             vessel diameter &lt;5mm in diameter for the 14F MANTA VCD or &lt;6 mm in diameter for the&#xD;
             18F MANTA VCD, or &gt; 50% diameter femoral or iliac artery stenosis&#xD;
&#xD;
          -  Patients in whom, during initial access of the artery, arteriotomy and surrounding&#xD;
             anatomy cannot be visualized and identified clearly under U/S imaging and/or if the&#xD;
             vertical depth from the surface of the skin to target area of the common femoral&#xD;
             artery measures greater than 6cm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wood</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vancouver General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vijay Iyer</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Darra Bigelow</last_name>
    <phone>610-331-7299</phone>
    <email>darra.bigelow@teleflex.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jill Hutton-Pugh</last_name>
    <phone>610-316-0845</phone>
    <email>jill.Hutton-Pugh@teleflex.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michelle Deville</last_name>
      <email>Michelle.Deville@Medstar.net</email>
    </contact>
    <investigator>
      <last_name>Itsik Ben-Dor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lowell Satler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alyson Ervinck</last_name>
      <email>aevinc1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Pedro Villablanca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian O'Neill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robin Stein</last_name>
      <phone>716-888-4859</phone>
      <email>rmstein3@buffalo.edu</email>
    </contact>
    <investigator>
      <last_name>Vijay Iyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Carmen Sutton</last_name>
      <email>Carmen.Sutton@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Angel Caldera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Northern Virginia Medical Center</name>
      <address>
        <city>Woodbridge</city>
        <state>Virginia</state>
        <zip>22191</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tina Calayo</last_name>
      <email>TINA CALAYO &lt;CACALAYO@sentara.com&gt;</email>
    </contact>
    <investigator>
      <last_name>Paul Mahoney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Health</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Jackie Chow</last_name>
      <email>Jackie.Chow@vch.ca</email>
    </contact>
    <investigator>
      <last_name>David Wood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MANTA</keyword>
  <keyword>Arterial Closure Device</keyword>
  <keyword>Ultrasound Closure</keyword>
  <keyword>Large Bore Closure Device</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data obtained will be used, without mentioning Subject PHI, to assess the results of the research, and the data could be used in the future with regard to this study or other studies. The data can be passed on to the health authorities for the purposes of registering the medical device.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

